These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 31548498)

  • 1. Estrogen Receptors in Epithelial-Mesenchymal Transition of Prostate Cancer.
    Di Zazzo E; Galasso G; Giovannelli P; Di Donato M; Bilancio A; Perillo B; Sinisi AA; Migliaccio A; Castoria G
    Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31548498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response.
    Begemann D; Anastos H; Kyprianou N
    Int J Urol; 2018 Apr; 25(4):318-326. PubMed ID: 29345000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
    Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
    Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nimotuzumab inhibits epithelial-mesenchymal transition in prostate cancer by targeting the Akt/YB-1/AR axis.
    Hu S; Duan YX; Zhou Q; Wang Y; Lu Q
    IUBMB Life; 2019 Jul; 71(7):928-941. PubMed ID: 30907986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes.
    Olsen JR; Azeem W; Hellem MR; Marvyin K; Hua Y; Qu Y; Li L; Lin B; Ke X; Øyan AM; Kalland K
    BMC Cancer; 2016 Jul; 16():377. PubMed ID: 27378372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial-to-Mesenchymal Transition-Related Markers in Prostate Cancer: From Bench to Bedside.
    Gogola S; Rejzer M; Bahmad HF; Abou-Kheir W; Omarzai Y; Poppiti R
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging therapeutics targeting castration-resistant prostate cancer: the AR-mageddon of tumor epithelial-mesenchymal transition.
    Hendrix LN; Hamilton DA; Kyprianou N
    Expert Rev Endocrinol Metab; 2013 Jul; 8(4):403-416. PubMed ID: 30736155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen deprivation therapy-induced epithelial-mesenchymal transition of prostate cancer through downregulating SPDEF and activating CCL2.
    Tsai YC; Chen WY; Abou-Kheir W; Zeng T; Yin JJ; Bahmad H; Lee YC; Liu YN
    Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1717-1727. PubMed ID: 29477409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen and Androgen Blockade for Advanced Prostate Cancer in the Era of Precision Medicine.
    Fujimura T; Takayama K; Takahashi S; Inoue S
    Cancers (Basel); 2018 Jan; 10(2):. PubMed ID: 29360794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profiling Prostate Cancer Therapeutic Resistance.
    Wade CA; Kyprianou N
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer.
    Chen WY; Tsai YC; Yeh HL; Suau F; Jiang KC; Shao AN; Huang J; Liu YN
    Sci Signal; 2017 Aug; 10(492):. PubMed ID: 28811384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epithelial-mesenchymal transition in prostate cancer: an overview.
    Montanari M; Rossetti S; Cavaliere C; D'Aniello C; Malzone MG; Vanacore D; Di Franco R; La Mantia E; Iovane G; Piscitelli R; Muscariello R; Berretta M; Perdonà S; Muto P; Botti G; Bianchi AAM; Veneziani BM; Facchini G
    Oncotarget; 2017 May; 8(21):35376-35389. PubMed ID: 28430640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppressive Role of Androgen/Androgen Receptor Signaling via Chemokines on Prostate Cancer Cells.
    Izumi K; Mizokami A
    J Clin Med; 2019 Mar; 8(3):. PubMed ID: 30871130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Achieving resistance specificity in prostate cancer.
    Wadhwa B; Dumbre R
    Chem Biol Interact; 2016 Dec; 260():243-247. PubMed ID: 27720870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: an opportunity for intervention.
    Front Oncol; ; . PubMed ID: 25566507
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.